Comparative Pharmacology
Head-to-head clinical analysis: LOZOL versus ZAROXOLYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOZOL versus ZAROXOLYN.
LOZOL vs ZAROXOLYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron, reducing plasma volume and extracellular fluid volume; also causes direct vasodilation through modulation of calcium channels.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the thiazide-sensitive sodium-chloride symporter (NCC).
Indapamide: Oral, 1.25 mg once daily. May increase to 2.5 mg once daily if no response after 4 weeks.
2.5 to 5 mg orally once daily; may increase up to 20 mg daily based on response.
None Documented
None Documented
Terminal half-life: 14-18 hours (mean 16 hours); clinically significant for once-daily dosing
Terminal elimination half-life ranges from 6 to 15 hours (mean ~8 hours) in patients with normal renal function. In renal impairment, half-life is prolonged and accumulation may occur.
Renal: 70% unchanged, Biliary/Fecal: 30% as metabolites
Primarily renal (approximately 70% as unchanged drug and metabolites) and biliary (approximately 30% as unchanged drug and metabolites into feces).
Category C
Category C
Thiazide-like Diuretic
Thiazide-like Diuretic